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Background and Objectives. The purpose of this study was to assess the incidence of cen-
tral venous catheter (CVC)-related thrombosis and the contribution of two common inher-
ited coagulation disorders (factor V Leiden, prothrombin G20210A mutation) to this com-
plication in a large hospital population.
Design and Methods. In a prospective setting, patients were assessed daily for signs and
symptoms suggestive of thrombosis. Routine Doppler-ultrasound was performed weekly in
all patients until CVC removal. Doppler-ultrasound examinations were stored on videotape
and assessed by two blinded observers. In the case of clinically suspected thrombosis the
physicians followed routine diagnostic and therapeutic procedures. The presence of factor
V Leiden and prothrombin G20210A mutation and other potential risk factors were assessed
in all patients.  
Results. In 252 consecutive patients the cumulative incidence of-CVC related thrombo-
sis was 30% (clinically manifested thrombosis: 7%). The relative risk of factor V Leiden or
prothrombin G20210A mutation for thrombosis was 2.7 (CI95% 1.9 to 3.8). In addition, a
personal history of venous thrombosis was associated with CVC-related thrombosis, where-
as the severity of thrombosis was affected by the absence of anticoagulants and the pres-
ence of cancer. 
Interpretation and Conclusions. Thrombosis is frequently observed after central venous
catheterization. Common inherited abnormalities in blood coagulation contribute sub-
stantially to CVC-related thrombosis. In view of physicians’ reluctance to prescribe pro-
phylactic anticoagulant treatment in vulnerable patients, a priori determination of common
inherited and acquired risk factors may form a basis to guide these treatment decisions.
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The contribution of factor V Leiden and
prothrombin G20210A mutation to the risk 
of central venous catheter-related thrombosis
Acentral venous catheter (CVC) is com-monly used for a variety of indica-tions.1 The benefit derived from these
devices can be offset by thrombosis, which
may be complicated by pulmonary embolism
(PE) and CVC dysfunction.2-4 Often, throm-
bosis may force premature CVC removal,
which requires the insertion of a new CVC
with the associated risk of complications
(pneumothorax), and the need for anticoag-
ulant treatment with its concomitant bleed-
ing risk.
Reliable estimates of the incidence of
CVC-related thrombosis among a large hos-
pital population are lacking. Besides, in con-
trast to a large number of studies on the
association of factor V Leiden and pro-
thrombin G20210A mutation with deep vein
thrombosis of the leg and pulmonary
embolism,5 studies investigating the associ-
ation of these risk factors with CVC-related
thrombosis are scarce.6-9 Such data are rele-
vant since they may indicate differences in
thrombotic risk in patients who need to
undergo central venous catheterization.
Moreover, these data could assist clinicians
in their decisions on anticoagulant prophy-
laxis.10
In a prospective setting we carefully
assessed the incidence of CVC-related
thrombosis in patients undergoing catheter-
ization via the jugular or subclavian vein.
We determined the contribution of the two
most common prothrombotic inherited
abnormalities in blood coagulation, factor V
Leiden and prothrombin G20210A mutation,
to CVC-related thrombosis in these patients.
In addition all patients were assessed for
other potential risk factors for CVC-related
thrombosis.
A B S T R A C T
 
Design and Methods
Patients and study design
This prospective study was performed at the Leiden
University Medical Center (LUMC), a university hospi-
tal in The Netherlands. The study protocol was approved
by our local medical ethical committee and all partici-
pating patients gave written informed consent.
Consecutive patients, aged 16 years or older, with a
central venous catheter (CVC) in place for at least 48
hours were considered eligible to participate in the
study. Central venous catheters could be inserted via
the jugular or subclavian vein. Patients were recruit-
ed from the different departments throughout our
hospital. Patients received a CVC for chemotherapy,
for hemodynamic or perioperative monitoring, for flu-
id administration or for pharmacotherapy. 
Patients with abnormal Doppler-ultrasound findings
(performed within 48 hours after CVC insertion) were
excluded if they had a history of a CVC at the same
insertion site, or a history of an objectively confirmed
thrombosis at the same insertion side, since these were
regarded as pre-existing thrombosis. Patients who
were unable to undergo serial Doppler-ultrasound
evaluations were also excluded.
The decisions to give anticoagulant prophylaxis and,
if so, the dosage, were at the discretion of the attend-
ing physicians. Post-operative patients, patients who
were immobile or sedated, and patients with a long-
term CVC (Port-a-cath®), who received prophylactic
doses of nadroparin subcutaneously at a dosage
between 2850 IU and 7600 IU daily were classified as
receiving prophylactic anticoagulant treatment. A
higher daily dosage of nadroparin, intravenous unfrac-
tionated heparin (prolonging the APTT by 2 to 2.5 fold)
or oral vitamin K antagonist (INR: 2.0 – 4.0) were clas-
sified as therapeutic anticoagulant treatment.
Monitoring and follow-up
During their admission, all patients were examined
daily by physicians for symptoms and signs suggestive
of CVC-related thrombosis; i.e. pain, discoloration,
local swelling or edema and visible collateral circula-
tion. If patients were discharged from the hospital
while their CVC was still in place, patients were seen
in the outpatient clinic at least every three to six
weeks. Clinical follow-up ended six weeks after
removal of the CVC, or one year after insertion if the
CVC was still in place. Patients with clinically suspect-
ed thrombosis were referred to our department of Radi-
ology for Doppler-ultrasound examination. If no throm-
bosis was objectively identified by Doppler-ultrasound,
patients underwent unilateral venography. 
Separate from the clinical follow-up, all patients were
examined serially for CVC-related thrombosis by
Doppler-ultrasound by one ultrasonographer according
to a standardized protocol. During admission, Doppler-
ultrasound was performed within 48 hrs after the inser-
tion of the CVC, and at least once a week until CVC
removal. Outpatients were examined by Doppler-ultra-
sound every three to six weeks.  Doppler-ultrasound
examinations were performed bilaterally and the fol-
lowing venous segments were subsequently identified:
the brachial, axillary, subclavian and jugular vein. All
real-time examinations were coded and recorded on
videotape. Recordings were assessed at least three
months after discharge of the patient from follow-up
by a panel of two blinded observers, experienced in
Doppler-ultrasound evaluation. A third expert opinion
was asked for, when needed. The outcomes of the
screening Doppler-ultrasound examinations were not
made known to the physicians responsible for clinical
follow-up nor to the radiologists who performed the
Doppler-ultrasound examinations or venography in the
case of clinically suspected thrombosis, since it is rou-
tine clinical practice to diagnose and treat CVC-relat-
ed thrombosis based on clinical signs and symptoms.
Blood samples were taken from all patients within
the 48 hrs after catheterization. Factor V Leiden and
prothrombin G20210A mutation and factor VIII:C
(IU/dL) were determined by standard techniques as
described previously.11-13 Factor V Leiden and pro-
thrombin G20210A mutation were analyzed by com-
paring carriers of the mutation to homozygous wild-
type individuals. Factor VIII levels were categorized in
levels over and under the 90th percentile of the dis-
tribution in this group of patients. In addition, estab-
lished risk factors for venous thrombosis and CVC
characteristics were assessed in detail in each patient.
Outcome measures
The primary end-point in this study was CVC-relat-
ed thrombosis. Two types of thrombosis were distin-
guished, clinically manifest thrombosis and subclini-
cal thrombosis. Clinically manifest thrombosis was
defined as thrombosis objectively identified by
Doppler-ultrasound or venography following signs or
symptoms suggestive of CVC-related thrombosis, as
noted by attending physicians. Subclinical thrombosis
was defined as thrombosis demonstrated by screening
Doppler-ultrasound in the absence of signs or symp-
toms.
A Doppler-ultrasound diagnosis of CVC-related
thrombosis was made according to predefined criteria.
For veins accessible to direct insonation, the criteria of
non-compressibility, visualization of an echogenic
intravascular mass and absence of respiratory phasicity
were used (jugular, axillary and subclavian veins).14-17 For
veins inaccessible to direct insonication the criterion of
mono-phasic flow (spectral Doppler) was used (middle
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part of subclavian vein, brachiocephalic vein and supe-
rior vena cava) to detect occlusive thrombosis.18
Criteria for diagnosing by contrast venography
included an intraluminal contrast filling defect of a
venous segment or persistent non-filling of a venous
segment in the presence of collateral circulation.19 Pos-
sible complications associated with CVC-related
thrombosis, pulmonary embolism (PE) and CVC dys-
function (occlusion) were carefully noted.
Statistical analysis
Cumulative incidences for subclinical thrombosis
and clinically manifest thrombosis were calculated as
the number of first events over the number of patients
at baseline. The ratios of the cumulative incidences
were the relative risks (RR). Ninety-five percent con-
fidence intervals (CI95%) were based on standard
errors for binomial distributions. The effects of risk
factors that were likely to be associated were deter-
mined by restriction analysis.
Results
Patients
In the 18-month study period, 368 patients with a
central venous catheter (CVC) were considered for
enrollment. Informed consent was not obtained from
88 eligible patients. In nine patients, the attending
physician did not allow us to recruit the patient. Four-
teen patients met one of the exclusion criteria: inabil-
ity to undergo Doppler-ultrasound (n = 9), an abnor-
mal Doppler-ultrasound (performed within 48hrs after
CVC placement) in patients with a history of a prior
CVC at the same insertion site (n = 3), or a history of
thrombosis on the same side prior to CVC insertion (n
= 2). Thus, 257 patients were enrolled in the study
protocol. Five patients were subsequently excluded
from analysis: in one patient the determination of fac-
tor V Leiden and prothrombin mutation had failed, in
three patients it was not possible to perform the
scheduled Doppler-ultrasound because of prior hospi-
tal discharge, and one patient withdrew informed con-
sent. Thus, complete data were obtained for analysis
from 252 patients. The main characteristics of these
252 patients and their CVC are shown in Table 1.
CVC-related thrombosis
Overall, 29.8% (75 out of 252) of patients developed
CVC-related thrombosis (CI95% 24.1% to 35.4%). In
18 patients (7.1%) the thrombosis was clinically man-
ifest, while in 57 patients (22.6%) subclinical throm-
bosis was demonstrated by routine Doppler-ultrasound.
Four patients (1.6%) developed pulmonary embolism
(PE), objectively diagnosed by a high probability ven-
tilation perfusion scintigram (n = 3) or abnormal hel-
ical CT (n = 1). In 12 patients (4.8%) one or more lumi-
na of the CVC became occluded. Pulmonary embolism
and CVC occlusion were not associated with clinical-
ly manifest thrombosis. Subclinical thrombosis was
diagnosed in one patient with PE and in another
patient with CVC occlusion.
Risk estimates for CVC-related thrombosis
Seventeen patients were heterozygous carriers of
the factor V Leiden mutation (6.7%) and another 6
patients had heterozygous prothrombin G20210A
mutation (2.4%). No patient was double heterozygous
or homozygous. Thrombosis was diagnosed in 12 of
the 17 patients with factor V Leiden (70.6%), as com-
pared to in 63 of 235 patients who did not have the
mutation (26.8%) (RR 2.6, CI95% 1.8 to 3.8). Throm-
bosis was diagnosed in 4 of 6 patients (66.7%) with
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Table 1. Baseline characteristics for 252 patients with a
central venous catheter (CVC).
Mean (range)
Age (yr) 54 (16-88)
Height (m) 1.73 (1.47-2.04)
Weight (kg) 75 (43-140)
Body mass index (kg/m2) 25 (16–41)
CVC in place (median days) 14 (2-365)
Numbers (%)
Sex 
Male 149 (59.1)
Female 103 (40.9)
Underlying Disease
Medical conditions 170 (67.5)
Solid tumor malignancy 39 (15.5)
Hematologic malignancy 97 (38.5)
Infectious disease 13 (5.2)
Cardiopulmonary disease 11 (4.4)
Inflammatory disease 8 (3.2)
Other 2 (0.8)
Postoperative condition 82 (32.5)
Anticoagulant treatment
No anticoagulants 107 (42.5)
Prophylactic dose 127 (50.4)
Therapeutic dose 18 (7.1)
Type CVC
Single/double lumen 61 (24.2)
Triple/four lumen 86 (34.1)
Swan-Ganz catheter 69 (27.4)
Porth-a-cath® 35 (13.9)
Other 1 (0.4)
Location CVC
Right side 164 (65.1)
Jugular vein 143 (56.7)
prothrombin G20210A mutation, whereas 71 throm-
boses were detected in 246 patients (28.9%) without
the mutation (RR 2.3, CI95% 1.3 to 4.2). For patients
with CVC-related thrombosis who had at least one of
the mutations the relative risk was 2.7 (CI95% 1.9 to
3.8) (Table 2). The population-attributable risk of the
mutations to thrombosis was 13.4%.
The risk estimates of other factors for CVC-related
thrombosis are summarized in Table 3. In univariate
analysis, a personal history of venous thrombosis was
associated with an increased risk of CVC-related
thrombosis. If patients with an inherited coagulation
disorder were excluded from the analysis, a personal
history of a venous thrombosis was still associated with
an increased risk of CVC-related thrombosis (RR 2.3,
CI95% 1.6 to 3.4). When the risk factor analysis was
performed within the group of patients with inherited
coagulation disorders (n = 23) or within the different
groups of patients according to the underlying disease
(cancer vs. no cancer) or anticoagulant-status (absence
vs. presence), no other substantial contributors to CVC-
related thrombosis could be identified. 
With regard to clinically manifest thrombosis, a sim-
ilar trend in relative risk was observed for the inherit-
ed coagulation disorders and a personal history of
thrombosis. Three out of 23 patients (13%) with an
inherited coagulation disorder, in all cases heterozy-
gous factor V Leiden, developed clinically manifest
thrombosis, as compared to 15 out of 229 (6.6%)
patients without the mutation, (RR 2.0, CI 95% 0.6 to
6.4). The RR from a personal history of thrombosis was
2.3 (CI 95% 0.8 to 6.5). Other factors were also asso-
ciated with the occurrence of clinically manifest
thrombosis. The lack of anticoagulant therapy was
strongly associated with an increased risk of clinically
manifest thrombosis (RR 4.7, CI 95% 1.6 to 14), espe-
cially in cancer patients who underwent intensive
chemotherapy. Among these patients, 14 of 98 with-
out prophylaxis developed clinically manifest throm-
bosis (14.3%), whereas no patients among the group
who received anticoagulants (n = 35) did so.
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Table 2. The risk of central venous catheter (CVC)-relat-
ed thrombosis in the presence or absence of inherited
coagulation disorders (factor V Leiden and prothrombin
G20210A mutation).
Factor V Leiden or CVC-related thrombosis
Prothrombin G20210A
mutation Yes No Total
Yes 16 7 23
No 59 170 229
Total 75 177 252
Table 3. Risk estimates for central venous catheter
(CVC)-related thrombosis.
Patients with Relative Risk 
thrombosis (%) (CI95%)
Sex
Male 39/149 (26.2%)
Female 36/103 (35%) 1.3 (0.9–1.9)
Age (years)
< 75 66/226 (29.2%)
≥ 75 9/26 (34.6%) 1.2 (0.7–2.1)
Body mass index (kg/m2)
< 30 62/219 (28.3%)
≥ 30 13/33 (39.4%) 1.4 (0.9–2.2) 
Personal history of
venous thrombosis
No 60/224 (26.8%)
Yes 15/28 (53.6%) 2.0 (1.3–3.0)
Active cancer treatment/intensive
chemotherapy*
No 34/114 (29.8%)
Yes 41/138 (29.8%) 1.0 (0.7–1.5)
Major surgery/trauma°
No 47/153 (30.7%)
Yes 28/99 (28.3%) 0.9 (0.6–1.4)
Oral contraceptives/hormone therapy
No 61/218 (28%)
Yes 14/34 (41.2%) 1.5 (0.9–2.3)
Factor VIII: C (IU /dL)†
< 290 64/227 (28.2%)
≥ 290 11/25 (44%) 1.6 (1.0–2.5)
Family history of venous
thrombo-embolism
No 64/223(28.7%)
Yes 11/29 (37.9%) 1.3 (0.8–2.2)
Insertion site
Jugular vein 42/143 (29.4%)
Subclavian vein 33/109 (30.3%) 1.0 (0.7–1.5)
Type of central venous catheter
Single/Double lumen 20/61 (32.8%)
Triple/Four lumen 29/86 (33.7%) 1.0 (0.6–1.6)
Swan-Ganz 18/69 (26.1%) 0.8 (0.5–1.4)
Port a cath® 8/35 (22.9%) 0.7 (0.3–1.4)
Other 0/1 Not calculated
Absence of anticoagulant
treatment
No 45/145 (31%)
Yes 30/107 (28%) 0.9 (0.6 – 1.3)
*Including all patients with hematologic malignacies (n = 97) or solid tumors
(n = 39) and two patients who had undergone stem cell transplantation for
rheumatoid arthritis. °Including 82 post-operative patients and 17 patients with
a primary medical condition who were operated on during the follow-up while the
CVC was in place. †FVIII levels: cut off level is the 90th percentile.
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Discussion
In a large cohort of prospectively followed patients,
we found a clear relationship between two throm-
bophilic mutations, factor V Leiden and prothrombin
G20210A, and CVC-related thrombosis. Overall, in the
presence of one of the two mutations the risk of CVC-
related thrombosis increased almost three-fold. Fac-
tor V Leiden or prothrombin G20210A contributed to
13.4% of the thrombotic events. In addition, a per-
sonal history of thrombosis was associated with CVC-
related thrombosis.
Reliable data concerning the association between
inherited coagulation disorders and CVC-related
thrombosis in adult patients are scarce and contra-
dictory. In a study of patients undergoing bone mar-
row transplantation, a 54% frequency of clinically
manifest thrombosis (seven of 13 patients) in patients
who were heterozygous for factor V Leiden was report-
ed, whereas in patients without factor V mutation a
10% risk was found (26 of 264 patients). The report-
ed relative risk (Cox proportional hazard model) from
this study was 7.7 (CI95%; 3.3 to 17.9).6 In a smaller
study in which 82 adult cancer patients with a CVC
were evaluated, prothrombotic risk factors, including
factor V Leiden, were not substantial predictors of clin-
ically manifest thrombosis, although the data sug-
gested that factor V Leiden increased the risk of
thrombosis.7 However, the statistical power of this
study was limited because of the small numbers of
patients with thrombosis and factor V Leiden.7
In one other study it was reported that factor V Lei-
den did not contribute to CVC-related thrombosis.8 In
this case-control study, the prevalence of factor V Lei-
den in patients with thrombosis (7.4%; two of 27
patients) was not observed to be higher than the
prevalence in the general Western population (5%).
The contribution of prothrombin G20210A mutation to
CVC-related thrombosis was not assessed in these
studies.6-8
In previous studies, clinically manifest thrombosis was
used as a primary end-point.6-8 Due to the systematic
screening of our patients, we found a total of 75 cases
with thrombosis (nearly 30%), which clearly enhanced
the statistical power of our study. This figure indicates
that clot formation is a common phenomenon after
CVC placement, while patients are at high risk for pro-
gression to clinically manifest thrombosis and associ-
ated morbidity. Our results emphasize the need for
implementation of adequate prevention strategies.20
Although the overall frequency of CVC-related throm-
bosis was not reduced by anticoagulants, the severity
of thrombosis was. Clinically manifest thrombosis was
observed substantially more often in patients who
received no anticoagulant prophylaxis, who were main-
ly patients with active cancer treatment.
Indeed, data from randomized controlled trials have
supported the use of routine anticoagulant prophy-
laxis in patients with a CVC, which has resulted in con-
sensus guidelines.21-23 However, many clinicians are
reluctant to prescribe anticoagulant prophylaxis rou-
tinely in patients with cancer and a CVC because of the
low expected incidence of thrombosis and the fear of
hemorrhage during anticoagulant prophylaxis.10,24
Recently it was reported that only 10-20% of physi-
cians routinely prescribe anticoagulant prophylaxis.10,24
Individual risk-assessment for CVC-related throm-
bosis, prior to the insertion of a CVC, could help clini-
cians in making decisions about prescribing anticoag-
ulant prophylaxis in vulnerable patients who have a
presumed increased risk of bleeding. From a clinical
point of view, determination of factor V Leiden and
prothrombin G20210A mutation may be useful in such
individual risk assessment, since these risk factors can
easily be determined before placement of the CVC.
Future studies in which the effectiveness of individu-
alized anticoagulant prophylaxis, after determination
of common inherited and established acquired risk fac-
tors, are clearly required to assess the effectiveness of
such a policy.
Factor VIII levels were generally high in our patients,
reflecting the acute phase reactive nature of this pro-
coagulant factor. Patients with the highest levels
appeared to be at a slightly higher risk of thrombosis
which further supports a prognostic role of a pro-
thrombotic state in the occurrence of CVC-related
thrombosis. In this study, all patients were examined
systematically for thrombosis with serial Doppler-
ultrasound. The reported sensitivity of criteria used for
Doppler-ultrasound diagnosis of subclavian thrombo-
sis ranged from 78 to 96%.14-18 Thus, the rate of throm-
bosis we found in patients with a subclavian CVC could
be an underestimation, but this would not have mate-
rially affected our risk estimates for prothrombotic
abnormalities. The reported specificity of Doppler-
ultrasound varied from 92 to 100%.14-18 This precludes
false labeling of patients with genetic abnormalities.
Contrast venography, although the gold standard, is an
invasive test and serial performance for screening is
not feasible.
In conclusion, thrombosis frequently occurs after
central venous catheterization. Common inherited
coagulation disorders and a personal history of throm-
bosis contributed to CVC-related thrombosis and
increased the risk almost three-fold. In vulnerable
patients, the determination of these factors prior to
CVC insertion could help clinicians to decide on anti-
coagulant prophylaxis. Future studies are needed to
evaluate implementation of preventive strategies,
including individual risk-assessment and subsequent
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anticoagulant prophylaxis of high-risk patients versus
long-term routine anticoagulant prophylaxis in all
patients.
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